Home
News
Screeners
Insights
Sai Parenteral's
540.
85
-2.55
(-0.47%)
Market Cap
₹2,389.43 Cr
PE Ratio
115.49
Industry
Healthcare
Buy
Sell
Company Performance:
1D
-0.47%
1M
-4.76%
6M
+33.31%
1Y
+33.31%
5Y
+33.31%
View Company Insights
Latest news about Sai Parenteral's
Sai Parenterals redirects ₹1,018.57 crore IPO funds for M&A
1 day ago
Sai Parenterals Limited proposes to utilise ₹1,018.57 million of unutilised IPO proceeds to acquire 60% stakes in Saicriti Pharma and Prathyak Laboratories. This strategic shift replaces organic expansion plans due to regulatory constraints under the Hyderabad Industrial Lands Transformation Policy. The move aims to secure immediate manufacturing capacity and R&D capabilities while navigating urban relocation mandates.
Sai Parenterals profit jumps 975% in Q1FY27; approves stake acquisitions
4 days ago
Sai Parenterals Q1 Results: ₹571 Cr Capex Plan, Noumed Integration
10 days ago
Sai Parenterals appoints auditors for FY27 and authorizes growth
Jul 07, 2026
Sai Parenterals subsidiary wins AUD 202 Mn OTC order
Jul 02, 2026
More news about Sai Parenteral's
01
Jul 26
Sai Parenterals to host virtual analyst meet on Jul 2
Sai Parenteral's Limited will conduct a virtual analyst and institutional investor meeting on July 2, 2026, hosted by Axis Capital. The session, scheduled from 10:00 AM to 11:00 AM IST, will focus on business performance and outlook without sharing unpublished price sensitive information.
30
May 26
Sai Parenterals targets ₹750 crore revenue in FY27
Sai Parenterals Limited reported a 133% year-on-year growth in consolidated revenue to ₹381 crore for FY26, following the acquisition of Noumed Pharmaceuticals. The company has provided guidance for FY27, targeting a revenue of ₹750 crore with an EBITDA margin of 17%, supported by long-term contracts and vertical integration. A capital expenditure program of ₹440 crore is underway, with full benefits expected in FY28.
29
May 26
Sai Parenterals secures $11 million anti-TB supply order
Sai Parenterals Limited has secured purchase orders worth USD 11 million (₹104.50 crore) from PILL CORP Philippines for the exclusive supply of anti-TB products. The 10-year contract, effective June 1, 2026, is not a related party transaction, and no promoters hold interest in the client.
28
May 26
Sai Parenterals FY26 PAT rises 45.5% to ₹14.37 Cr
Sai Parenterals reported FY26 PAT of ₹14.37 crore, up 45.5%, driven by CDMO exports and the Noumed acquisition. Consolidated revenue surged 140.4% to ₹380.99 crore.
Sai Parenteral's
540.
85
-
2.
55
(-
0.
47
%)
1 Year Returns:
+33.31%
Industry Peers
Sun Pharmaceutical
1,902.40
(-
0.
08
%)
Divis Laboratories
8,597.00
(+
0.
32
%)
Torrent Pharmaceuticals
4,896.50
(-
2.
17
%)
Cipla
1,432.20
(-
0.
40
%)
Zydus Life Science
1,120.00
(+
1.
11
%)
Lupin
2,201.80
(+
0.
01
%)
Mankind Pharma
2,384.00
(-
0.
04
%)
Dr Reddys Laboratories
1,174.70
(-
0.
45
%)
Laurus Labs
1,802.00
(-
1.
26
%)
Aurobindo Pharma
1,621.30
(+
0.
83
%)
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/ Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation
IPO
Cyclical Trend
Events Calendar